Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026
PR Newswire•05/11/2026•16:38 ET
1
Key Highlights
- ➤Curis will report third-quarter 2026 results November 12 at 4:00 p.m. ET
- ➤Management will host a conference call and webcast November 12 at 4:30 p.m. ET
- ➤Emavusertib is being evaluated in lymphoma and CLL Phase 1/2 and Phase 2 studies
- ➤Curis plans continued emavusertib AML development with additional funding
Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026 PR Newswire
LEXINGTON, Mass., Nov. 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its third quarter 2026 financial and operating results on Thursday, November 12, 2026, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET.
Get started
Create a free account to read the full story.